The Matterhorn Trial, a landmark phase III study published in the New England Journal of Medicine, evaluates durvalumab, an anti-PD-L1 monoclonal antibody, combined with FLOT chemotherapy in resectable gastric and gastroesophageal junction (GEJ) cancer. Consequently, this global, double-blind, placebo-controlled trial demonstrates significant improvements in event-free survival (EFS). For oncologists and cancer researchers, these findings address … Continue reading Gastric Cancer Treatment: Durvalumab’s Matterhorn Trial Data